Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Elanco (ELAN)

Elanco Adds Stacey Ma to Board; Board Size Rises from 14 to 15 Members

Neutral Impact 2 of 5 leadership Written later

Elanco Animal Health appointed Dr. Stacey Ma, currently Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, to its Board of Directors effective immediately. The filing says the board was expanded from 14 to 15 members to accommodate the appointment. The change is governance-related and the filing reports no financial results or guidance.

Key points

  • Board appointment effective immediately; Dr. Ma named to Class III with a term expiring in 2027
  • Board size increased from 14 to 15 members
  • Dr. Ma also appointed to the Innovation, Science and Technology Committee
  • Announced in a press release dated November 12, 2024; board appointment made November 11, 2024

The filing

CompanyElanco (ELAN)
Form8-K, current report
Filed with the SECNov 12, 2024, 5:28 PM ET
Accession number0001104659-24-116942

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 12, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.